Sign in

CIK 0001806952

  • Non-accelerated filer
  • Smaller reporting company

Lyell Immunopharma, Inc.

Sign in to watch
Ticker
LYEL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
833006753
Phone
+1 650-695-0677
Business address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$49,999,983
in 2 filings
Open-market sales, last 90 days
$215,781
in 9 filings

Net +$49,784,202. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 41 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-06-29 Innovative Cellular Therapeutics Holdings Ltd 10% owner Other disposition −76,000 2,857,500
2026-06-15 Innovative Cellular Therapeutics Holdings Ltd 10% owner Other disposition −66,500 2,933,500
2026-06-10 Bachleda Mark Director Grant or award · Option (right to buy) +9,250 9,250
2026-06-10 NABEL ELIZABETH G Director Grant or award · Option (right to buy) +9,250 9,250
2026-06-10 Klausner Richard Director Grant or award · Option (right to buy) +9,250 9,250
2026-06-10 Ramachandra Sumant Director Grant or award · Option (right to buy) +9,250 9,250
2026-06-10 FRIEDMAN CATHY Director Grant or award · Option (right to buy) +9,250 9,250
2026-06-10 BRAWLEY OTIS W Director Grant or award · Option (right to buy) +9,250 9,250
2026-06-10 RIEFLIN WILLIAM JL Director Grant or award · Option (right to buy) +9,250 9,250
2026-06-10 Shook David Chief Medical Officer Sale −1,977 $12.64 $25K 20,923
2026-05-11 Bulis Veronica Sanchez VP, Corporate Controller Sale −217 $18.91 $4K 15,420
2026-05-11 Lee Gary K. Chief Scientific Officer Sale −130 $18.92 $2K 17,808
2026-05-11 Hill Stephen J. Chief Operating Officer Sale −89 $18.92 $2K 17,894
2026-05-11 Seely Lynn President and CEO Sale −388 $18.91 $7K 73,878
2026-03-09 Shah Smital Chief Fin. and Bus. Officer Grant or award · Option (right to buy) +140,000 140,000
2026-03-06 ARCH Venture Partners IX, LLC 10% owner Purchase +488,090 $25.61 $12.5M 1,426,528
2026-03-06 ARCH Venture Fund XIII, L.P. 10% owner Purchase +488,090 $25.61 $12.5M 1,426,528
2026-02-11 Lee Gary K. Chief Scientific Officer Sale −1,671 $23.39 $39K 16,938
2026-02-11 Hill Stephen J. Chief Operating Officer Sale −1,236 $23.39 $29K 17,795
2026-02-11 Seely Lynn President and CEO Sale −7,455 $23.39 $174K 74,266

Page 2 of 8 · 156 trades